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Abstract
Genes and their expression regulation are among the key factors in the comprehension of
the genesis and development of complex diseases. In this context, microRNAs (miRNAs)
are post-transcriptional regulators that play an important role in gene expression since they
are frequently deregulated in pathologies like cardiovascular disease and cancer. In vitro
validation of miRNA - targets regulation is often too expensive and time consuming to be
carried out for every possible alternative. As a result, a tool able to provide some criteria to
prioritize trials is becoming a pressing need. Moreover, before planning in vitro experiments,
the scientist needs to evaluate the miRNA-target genes interaction network. In this paper
we describe themiRablemethod whose purpose is to identify new potentially relevant
genes and their interaction networks associate to a specific pathology. To achieve this goal
miRable follows a system biology approach integrating together general-purpose medical
knowledge (literature, Protein-Protein Interaction networks, prediction tools) and pathology
specific data (gene expression data). A case study on Prostate Cancer has shown thatmiR-
able is able to: 1) find new potential miRNA-targets pairs, 2) highlight novel genes potentially
involved in a disease but never or little studied before, 3) reconstruct all possible regulatory
subnetworks starting from the literature to expand the knowledge on the regulation of
miRNA regulatory mechanisms.
Introduction
Nowadays a huge amount of biological data (e.g. gene and protein expression data) is available
to scientists to be used to dissect the complexity of a disease. However, extracting useful infor-
mation from biological databases is a complex task, in fact, it has to be understood and mined
searching for the sparkling gems. This is a though job to do without the help of tools able to
identify the most promising options. This task becomes even harder when we consider gene
regulation and miRNAs as post-transcriptional regulators. miRNAs are small non-coding
PLOSONE | DOI:10.1371/journal.pone.0122473 April 7, 2015 1 / 15
a11111
OPEN ACCESS
Citation: Baglioni M, Russo F, Geraci F, Rizzo M,
Rainaldi G, Pellegrini M (2015) A New Method for
Discovering Disease-Specific MiRNA-Target
Regulatory Networks. PLoS ONE 10(4): e0122473.
doi:10.1371/journal.pone.0122473
Academic Editor: Varda Rotter, Weizmann Institute
of Science, ISRAEL
Received: August 18, 2014
Accepted: February 11, 2015
Published: April 7, 2015
Copyright: © 2015 Baglioni et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: FR has been supported by a fellowship
sponsored by Progetto Istituto Toscano Tumori Grant
2012 Prot.A00GRT. The present work is partially
supported by the Flagship project InterOmics(PB.
P05), funded by the Italian MIUR and CNR
organizations, and by the joint IIT-IFC Laboratory of
Integrative Systems Medicine (LISM). The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
RNAs that negatively regulate gene expression at post-transcriptional level, usually binding the
3’-UTR of mRNAs [1]. Several tools for the prediction of miRNA-mRNA interactions are
available. However they generally predict whether a gene is a target for a miRNA analyzing
only the sequence (TargetScan [2], miRanda [3] and Pita [4]). Other tools are based on se-
quence and gene expression data (Magia2 [5]). Methods based only on the analysis of the se-
quence tend to return a large number of false positive targets. Computational methods predict
hundreds of thousands target mRNAs per miRNA [6]. According to several studies, the ex-
pected rate of false positive returned by these predictors can range from 24% to 70% [7–9].
Methods based on the integration of mRNA and miRNA expressions can improve the predic-
tion accuracy, even if they do not take into account the importance of each gene in relation to
its disease-specific regulatory network.
In this work we attempt to overcome these problems by integrating disease-specific knowl-
edge collected from the literature as well as the mRNA—miRNA expression data and the pro-
tein-protein interaction networks. Protein-Protein Interaction networks play an important role
in the identification of disease associated genes, and can be further explored in order to identify
disease related subnetworks (see [10] and references therein).
In this paper we describemiRable, a new method that takes into account the disease-specific
context, mRNA—miRNA expression data and protein-protein interaction networks to provide
a landscape of the complex miRNA-gene regulatory networks that are at the root of a specific
pathology. As a case study, we tested our method on Prostate Cancer (PCa) discovering a
promising gene and two miRNAs still unstudied in conjunction with this pathology.
Materials and Methods
In this section we provide a detailed description of the workflow of themiRable pipeline. As de-
picted in Fig 1, our method consists of three main steps: base regulatory network creation, net-
work enrichment using pathology-specific data, and network analysis.
Step One—Regulatory Network Creation
Literature Searching. Most often literature searching is the initial activity that researchers
accomplish to identify a set of genes involved in a particular disease. Our method starts from
this step and follows the approach proposed by Jourquin et al. [11] re-implementing it
completely. In particular, we query PubMed (http://www.ncbi.nlm.nih.gov/pubmed) to re-
trieve a list of publications relevant to a particular pathology. The resulting list consists of a
plethora of papers that, in most cases, do not contain references to genes. In order to focus only
on the subset of articles containing gene information, we filtered the results according to the
NCBI’s gene2pubmed database where the association between genes, PubMed papers and spe-
cies is provided. This filtering ensures us to select only papers containing gene information.
Once we have obtained a list of disease-related genes, we need a scoring strategy to give rele-
vance to a gene with respect to all the others. To solve this issue we compute the hypergeomet-
ric score for all the retrieved genes, as Jourquin et al. [11] do, and we retain only the genes
whose hypergeometric score (from now on referred to as disease-score) is higherthan 4. The
disease score is computed by the following formula:
dsðm; n; j; kÞ ¼ log10Hðm; n; j; kÞ
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Fig 1. ThemiRableworkflow. The method starts from a query to PubMed with the key words ‘prostate cancer’. We retrieved 117197 PubMed IDs and more
than 7800 have gene information. We obtained 3757 gene IDs for human and of those, 250 genes have more than 9 supporting publications. 115 genes have
a disease-score greater than 4.
doi:10.1371/journal.pone.0122473.g001
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whereH(m, n, j, k) is computed by:
Hðm; n; j; kÞ ¼
Xminðn;jÞ
i¼k
m j
n i
 !
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m is the number of articles restricted to homo sapiens’ genes, n is the number of papers regard-
ing genes for homo sapiens related to the investigated pathology (in our case study prostate
cancer), j is the number of articles about homo sapiens related to a certain gene G, and k is
the number of papers about homo sapiens that are related to both the investigated pathology
and G.
Exploiting miRNA-target predictions and gene expression. Once relevant genes have
been selected mining the literature, they are required to be matched with the miRNAs for
which they are targets to build the regulatory network, see Fig 2a). To accomplish this, a predic-
tion step is applied on the retained genes, selecting all the miRNA-target pairs having as target
one of the genes retained in the previous step. In this study we used TargetScan 6.2 [2] (the
complete dataset with conserved and non-conserved binding sites) as miRNA-target
prediction tool.
The normalized expression data comes from the Prostate Adenocarcinoma (MSKCC, Can-
cer Cell 2010) dataset obtained from cBioPortal (http://cbio.mskcc.org/cancergenomics/
prostate/data/) [12]. This dataset consists of the complete mRNA (Affymetrix Human Exon
1.0 ST arrays) and miRNA (Agilent microRNA V2 arrays) expression profiles of 111 patients.
Not all the possible pairs are equally considered, because their importance also depends on
the expression of the miRNAs and the targets in the specific context. Since miRNAs generally
repress their target mRNAs, a natural way to validate mRNA targeted by a miRNA is that of
measuring whether their expressions are inversely correlated. In fact, the value of the anti-cor-
relation can be interpreted as a measure of the importance and strength of the miRNA-mRNA
interaction. As a correlation coefficient we computed the Pearson’s score. The Pearson’s corre-
lation coefficient is computed as rXY ¼ sXYsXsY where σXY is the covariance of X and Y, σX is the
standard deviation of X, σY is the standard deviation of Y, X is the vector of the mRNA expres-
sion for each PCa tissue, and Y is the vector of the miRNA expression for each PCa tissue. We
select the minimum absolute value such that the correlation is statistically significant (it
Fig 2. Modification of the regualtory network. a) Regulatory network. b) Regulatory network and PPINs. c) Extension of the regulatory network with
new targets.
doi:10.1371/journal.pone.0122473.g002
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depends on the number of samples in the expression dataset, and it is associated to a p-
value 0.05) and we filter out all the pairs whose correlation coefficient is not high enough.
The set RC of miRNA-target pairs retained can be defined as follows:
RC ¼ fðm; tÞjm 2 PðtÞ; t 2 GSðDÞ; jCorrCoeff ðm; tÞj  jmin corrj;CorrCoeff ðm; tÞ < 0g
where GS(D) is the subset of genes with a disease-score greater than 4 andm 2 P(t) means that
m is a miRNA predicted to target the mRNA t. The regulatory network consists of a bipartite
graph whose nodes are all the miRNAs and targets in RC and there exists an edge connecting a
miRNA-target pair if it belongs to RC.
Step two—Regulatory Network Extension
Once the regulatory network is built, the goal is to extend it by predicting new pairs miRNA-
mRNA that can be significant for the pathology, but never or poorly studied before. To this
end we postulate that a gene has a higher probability to be associated to a specific pathology if
it interacts with at least one of the known pathology-specific genes and also if it is involved in
some functions highly relevant for the pathology.
Functional enrichment—pathology-relevant function retrieval. In this step our method
associates to each gene in the regulatory-network the set of the Gene Ontology (GO) functions
[13] in which the gene is involved. This information is subsequently used to select the subset of
GO functions, called the Background Functions, that are more likely related to the pathology.
The relevance of the function to the pathology is statistically determined by exploiting Fisher’s
probability computation modified with Benjamini-Hockeberg’s method and selecting all the
functions with p 0.05. The contingency matrix for the Fisher’s computation for each GO
function f is as follows:
#ðf ;GQÞ #ðf ;GGOÞ
#ðf ;GQÞ #ðf ;GGOÞ


where #(f, GQ) is the number of genes considered in Step 1 that are involved in f, #(f, GGO) is
the total number of genes involved in f, #ðf ;GQÞ is the number of genes considered in Step 1
not involved in f, and #ðf ;GGOÞ is the total number of genes of the Gene Ontology that are not
involved in f. To clarify this concept, letm be the number of genes in the GO, n be the number
of genes returned in Step 1, j be the number of genes of the generic function f, and k j be the
number of genes returned in Step 1 that are also involved in f. The contingency matrix then is:
k j
n  k m  j


and the p-value for f is computed as: Fisherðf ;QÞ ¼
kþ j
k
 !
n kþm j
n k
 !
nþm
n
 ! .
The set of the Background Functions of a disease (FBF(D)) is defined as:
FBFðDÞ ¼ ff 2 GOjFisherBHðf ;QÞ  0:05g
where Q is the set of genes obtained from Step 1 and FisherBH(f, D) is the p-valuemodified ac-
cording to the Benjamini-Hockeberg method.
Network extension—importing the PPINs. Since all the genes belonging to the regulato-
ry-network come from the literature, to add new targets not studied yet in conjunction with
Discovering MiRNA-Target Regulatory Networks
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the pathology, we need to expand the set of genes. To achieve this, we add all the interactors of
one mRNA by importing the subset of the Biogrid [14] Protein Protein Interaction network
where the mRNA is an interactor. This procedure is repeated for each mRNA of the regulato-
ry-network (see Fig 2 b) for a small example). The network is extended iteratively each time
considering the interactors of the latest added mRNAs. The process stops when no more inter-
actors can be imported. The output of this phase is an extended network that can be seen as a
graph where each gene belongs at least to a path starting from a miRNA.
Target addition. According to the broadly accepted guilt by association principle, associat-
ed or interacting proteins are more likely to share functions. Hence, with the purpose of adding
new potentially relevant targets in the regulatory-network, we focus on the subset of the im-
ported mRNAs that are interactors of miRNA targets that is the set of previously imported
genes having a direct connection with at least one miRNA target. These interactors are en-
riched with their GO functions. All the interactors having at least one GO background function
are retained and considered as candidate targets. A candidate miRNA target is accepted if and
only if: a) it is predicted by TargetScan as target for at least one miRNA belonging to the regula-
tory network; b) it is strongly anticorrelated (p − value 0.01) with respect to at least one of
the miRNAs selected in step a). When a new mRNA verifies the two above conditions with a
set of miRNAsM, it is included in the regulatory network as a new target and it is connected to
all the miRNAs belonging toM. We repeat this procedure only once since a recursive applica-
tion can result in the introduction of weak connections or misleading targets. Fig 2 c) provides
an example of an extended regulatory-network. The complete list of miRNA-target pairs with
their anticorrelation value can be found in the S1 File of this paper.
Step three—Network analysis
Subnetworks extraction. Starting from the idea that a pathology is the result of a complex
set of interactions, and that a gene should always be considered not as a single entity, but as
part of a context, we decided to explore the regulatory part of the network (that is the miRNAs
and their direct targets after the target addition step) with the intent of extracting a subnetwork
for each mRNA and for each miRNA. We consider each node (either mRNA or miRNA) of the
regulatory network extended with the added targets, as a seed around which to build the sub-
network. Of this seed we take all the triangles. Consider for example the network in Fig 3 and
node 1 as seed.
The neighbours of 1 is N(1) = {2, 4, 5}. So we consider all the neighbours of the seed neigh-
bours without the seed itself: N(2) = {3, 4, 9, 11}, N(4) = {2, 3, 6}, and N(5) = {6, 7, 8}. Then we
intersect the sets N(1) \ N(2) = {4}, N(1) \ N(4) = {2}, and N(1) \ N(5) = F, and we obtain the
subnetwork of Fig 3b) up as subnetwork associated to the seed 1. The same Figure shows the
subnetwork associated to seed 2. This procedure is iterated associating a subnetwork to each
node of the extended regulatory network. The complete set of the extracted regulatory subnet-
works can be found in the S2 File of this paper.
Centrality index computation. Since the regulatory subnetworks are direct unweighted
graphs, it is possible to exploit standard measures derived from graph theory as tools to analyze
them. Centrality indices [15] are among the basic and most frequently used graph theoretical
measures to evaluate the importance of nodes within the network. Among the various centrali-
ty indices we computed: the betweenness centrality [16], the closeness centrality as defined in
[17] where the index can be computed also on directed graphs, the eccentricity index [18], and
the eigenvector centrality (a.k.a. power method index) [19]. According to [20] the power meth-
od index, of which we provide a brief definition below, is the most informative in cases like
ours. Hence we decided to exploit mainly this index. The power method is an index that allows
Discovering MiRNA-Target Regulatory Networks
PLOS ONE | DOI:10.1371/journal.pone.0122473 April 7, 2015 6 / 15
to measure the importance of the connections of a node by associating to each node a value
that combines together its connections and their importance so that a node with a few connec-
tions of great importance can be more important than a node with many connections of
low importance.
Let xi the vertex i centrality, we define xi as:
xi ¼
1
l
Xn
j¼1 Aijxj
According to the above formula, the centrality value of node i proportionally depends on the
centrality of its neighbours and vice versa. As a result, computing centrality for a graph of n
nodes reduces to the solution of a system of n equations in n unknowns. This problem can be
efficiently solved by using an iterative approach. Let x = (x1, . . ., xn) be a vector where the i-th
element contains the centrality of node i, then it is possible to compute x by solving the follow-
ing equation: λx = Ax According to the above formula, x is the eigenvector of the adjacency
matrix A with eigenvalue equal to λ.
Fig 3. Construction of regulatory-subnetworks. a) Network toy example. b) Direct subnetworks with respect to two different seeds.
doi:10.1371/journal.pone.0122473.g003
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Gene scoring. Result ranking is one of the most important things to consider to give ad-
vice about a pathology. In our case the best result is the gene showing the highest probability to
be causative of the pathology. Hence, we ranked the genes using their regulatory subnetworks
to obtain a score able to measure the impact of a gene in the disease. These subnetworks have
the peculiarity that all their nodes are part of the regulatory network that is a node belongs to a
regulatory subnetwork if it is contained in at least one intersection with the seed’s neighbour
and it is also either a miRNA or neighbour of a miRNA. To compute this score (regulatory sub-
network score) we used a vector of p-values coming from the functional enrichment of the sub-
network. More precisely, for each function in the set of Background we compute the Fisher
score for the function with respect to the subnetwork. The contingency matrix is built as seen
before, but this time the set of considered genes are those belonging to the regulatory subnet-
works and not those returned by the PubMed query. In this way we get a vector v of sizem
wherem is the number of functions in FBF(P). To associate a single value with each vector of p-
values, we took inspiration from Fisher’s combined probability test [21] and we computed the
following score.
SðvÞ ¼Pmi¼1;vi>0 Log10ðviÞ
We used this value to score the regulatory-subnetwork and so the seed it has started from: the
highest the better.
We included in our method a further abstraction layer considering subnetworks as nodes of
a meta-network where an edge is present if the seed of the edge target network belongs to the
subnetwork of the edge starting network. This meta-network still maintains all the desirable
theoretical properties of graphs and, thus, it can be analyzed with the same tools described ear-
lier. In particular, we exploited the Power Method index as a ranking function so that to identi-
fy the most important subnetworks.
Results and Discussion
In this study we proposedmiRable, a new method aimed at exploring the complex world of
miRNA regulation in the context of a disease. Starting from the literature information our
method applies different constraints and filters to build the extended regulatory network, and
exploits it to find all the regulatory subnetworks involved in a disease (in our case the PCa). By
using this approach our method has been able to find new candidate genes and miRNAs related
to PCa. Some of these genes have already been associated with PCa, but the majority of them
are novel candidate genes.
In order to rank these genes according to their relevance for the analyzed pathology, we em-
ploy the regulatory subnetwork score. This score is able to capture the relevance of a regulatory
subnetwork (and consequently its corresponding seed gene) for a disease on the base of the
Background Functions. Moreover, we applied the Power Method on the meta network to esti-
mate the importance of a seed in a regulatory subnetwork with respect to the other seeds. This
index does not take into consideration the Background Functions associated to the disease, but
only the seed’ connections. Both these scoring methods highlighted the same set of relevant
best genes and miRNAs.
In our analysis we found that the most relevant genes in the ranking received few literature
citations (see Table 1 and the S3 File), except for few cases such as the Androgen Receptor
(AR).
Discovering MiRNA-Target Regulatory Networks
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Novel candidate PCa-related genes
By exploiting the two measures (the regulatory subnetwork score and the Power Method score)
described in the previous section, our method predicted some genes that have already been
studied (i.e. EP300, CTNNB1, AKT1, AR), while others are less known in relation to PCa. In
the following, we provide some details about three promising predicted genes in the top rank
positions: ESR1, miR-548c-3p and miR-494.
• Estrogen Receptor 1 (ESR1). The Estrogen Receptor 1 is an inhibitor of cell migration and
its repression enhances cell migration and accelerates tumor formation and metastasis [22].
This gene is known to be involved in breast cancer. Recent publications focused on ESR1
polymorphisms to explore potential associations with prostate cancer risk. In a recent work
Fu et al. [23] conducted a meta-analysis indicating that ESR1 rs9340799 polymorphism is as-
sociated with prostate cancer risk. According to our results ESR1 is among the top ranked
genes (see Table 1 and Fig 4).
Even though its disease-score, based on publications, is only 3.13, its regulatory subnetwork
score is 1513.10 with 154 nodes in the subnetwork and the highest Power Method score
(0.19). Interestingly, although the ESR1 disease-score is below the defined threshold of 4 and
thus it is removed in the first-phase filtering, our method re-included this gene into the regu-
latory network in the second step of our algorithm (namely the regulatory-network exten-
sion), demonstrating the efficacy of the method to discover unstudied or poorly studied
potentially-relevant disease-related genes.
By using our method we found that ESR1 is a potential candidate target of miR-182. This
Table 1. Top 20 genes in our result ranking list, based on the regulatory subnetwork score. A disease-
score of -1,00 denotes a gene with less than 9 supporting publications related to PCa (at the time of the analy-
sis) or no publications at all. RSs: regulatory subnetwork score; Ds: disease score; PMs: power
method score.
Gene nr. nodes RSs Ds PMs
EP300 99 1775.47 0.10 0.12
HDAC1 103 1556.63 1.66 0.13
CTNNB1 78 1551.83 3.58 0.10
ESR1 154 1513.10 3.13 0.19
AKT1 89 1500.17 22.61 0.10
AR 69 1491.21 768.47 0.08
SMAD3 100 1464.57 0.68 0.12
SP1 64 1327.98 0.90 0.09
hsa-miR-548c-3p 151 1285.12 -1.00 0.11
BRCA1 142 1260.87 6.49 0.13
MAPK8 38 1232.48 0.91 0.05
JUN 56 1217.10 0.04 0.08
KAT2B 52 1187.84 -1.00 0.06
STAT3 53 1144.44 2.33 0.07
CHUK 39 1143.01 -1.00 0.06
MYC 135 1125.92 6.78 0.15
hsa-miR-494 147 1116.00 -1.00 0.13
SIRT1 62 1084.97 2.10 0.08
RB1 67 1053.97 0.69 0.08
GSK3B 62 1049.51 0.74 0.08
doi:10.1371/journal.pone.0122473.t001
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miRNA is over-expressed in PCa tissues and cell lines and it has been shown that it can pro-
mote cell invasion and proliferation, and knock-down of miR-182 also significantly de-
creased in vivo prostate tumor growth [24]. Hence, we can conclude that the over-expression
of miR-182 and the down-regulation of ESR1 could be associated with PCa progression and
potentially useful as prognostic biomarker. Moreover, Tang and colleagues [22] have recently
applied a computational approach identifying two putative novel miRNA regulatory path-
ways in PCa: 1) ligand-independent activation of ESR1 and ESR2 and 2) membrane-bound
ESR1 (interaction with growth factors signalling), showing a new possible role of miRNAs in
the regulation of ESR1 and the consistence of our results.
Fig 4. ESR1 regulatory subnetwork. Red node: ESR1; yellow node: miR-182; green nodes: genes in our top 20 ranking list (EP300, CTNNB1, AKT1,
BRCA1, SMAD3, HDAC1, MYC, SP1, STAT3, CHUK, SIRT1, JUN). Cytoscape (http://www.cytoscape.org/) has been used to visualize the network.
doi:10.1371/journal.pone.0122473.g004
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It is interesting to note that ESR1 and the other genes in our top 20 list interact with each
other. Among these, ESR1 interacts with: EP300, CTNNB1, AKT1, BRCA1, SMAD3,
HDAC1, MYC, SP1, STAT3, CHUK, SIRT1, JUN. Some of these genes have already been re-
ported to be abnormally expressed in prostate cancer, such as for example the Histone deace-
tylase 1 (HDAC1) [25] which is in the second position in the ranking list, based on the
regulatory subnetwork score.
• miR-494 and miR-548c-3p. According to our results, miR-494 and miR-548c-3p are the top
rank candidate miRNAs involved in PCa. This result is based on both: the number of interac-
tions (respectively 146 for miR-494 and 150 for miR-548c-3p), the regulatory subnetwork
score (1116.00 for miR-494 and 1285.12 for miR-548c-3p) and their Power Method score
(see Table 1). Nevertheless, the role of both these miRNAs in PCa is poorly known.
Little is known about miR-548c-3p while more information about the miR-548 family is
available. The latter is a large, poorly conserved primate-specific miRNA gene family [26]. It
has been postulated that the miR-548 family could derive fromMade1 transposable elements
[27]. Made1 elements are short miniature inverted-repeat transposable elements (MITEs),
which consist of two 37 base pair (bp) terminal inverted repeats that flank 6 bp of internal se-
quence. Thus, Made1 elements are nearly perfect palindromes, and when expressed as RNA
they form highly stable hairpin loops. The role of miR-548 family in cancer is still to be eluci-
dated, but some authors suggested cancer-related regulatory roles for this family [27].
The role of miR-494 is better known. In fact, several publications discuss its role in cancer
[28] [29] [30]. Liu et al. [28] identified miR-494, whose expression is induced by tumor-
Fig 5. Regulatory-subnetworks for miR-494 andmiR-548c-3p.On the left the number of targets of miR-548c-3p in its regulatory subnetwork; on the rigth
the number of targets of miR-494 in its regulatory subnetwork. In the middle the common targets of both miRNAs.
doi:10.1371/journal.pone.0122473.g005
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derived factors, as an essential player in regulating the accumulation and activity of Myeloid-
Derived Suppressor Cells (MDSCs). These MDSCs orchestrate the tumor microenvironment
and facilitate tumor angiogenesis and metastasis, by direct targeting of PTEN and activation
of the Akt pathway.
As shown in Fig 5, miR-494 and miR-548c-3p regulatory subnetworks share 54 putative tar-
gets including PTEN. Observing PTEN regulatory subnetwork (Fig 6), we can see 47 nodes,
of these 18 miRNAs (two of them, miR-494 and miR-141, have already been validated [31]),
and other important genes in our ranking list such as: ESR1, AR, AKT1, KAT2B.
It has been shown that miR-141 is up-regulated in PCa tissues and cell lines and it modulates
androgen receptor transcriptional activity in human PCa cells [32]. Moreover, according to
Fig 6. PTEN regulatory subnetwork. Red node: PTEN; yellow nodes: miR-548c-3p and miR-494; green nodes: genes in the top 20 ranking list (ESR1, AR,
AKT1, KAT2B). Cytoscape (http://www.cytoscape.org/) has been used to visualize the network.
doi:10.1371/journal.pone.0122473.g006
Discovering MiRNA-Target Regulatory Networks
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the miRandola database [33, 34], it is considered a new candidate non-invasive biomarker
because it is frequently over-expressed in the blood of PCa patients compared to healthy
controls.
Conclusions
In this work we presented a new method aimed at exploring the complexity of gene regulation
through miRNAs, in a disease-specific context. Our method allows to: 1) find new potential
miRNA-targets, 2) highlight novel genes potentially involved in a disease but never or poorly
studied before, 3) reconstruct all possible regulatory subnetworks starting from the literature to
expand the knowledge on the miRNA regulatory mechanisms.
We applied our method to prostate cancer finding new interesting protein-coding genes
and miRNAs potentially involved in the disease. The most promising protein-coding candidate
gene is ESR1. Its role is well-understood in breast cancer, instead its role in prostate cancer has
not been investigated adequately. Nevertheless, a number of similarities between the AR and
ESR1 signalling pathways are known. In the absence of a ligand they are inactive and com-
plexed with heat shock proteins [35]. When the ligand (androgen or estrogen) binds the recep-
tor, the receptor itself undergoes to a conformational change promoting its nuclear
localisation, dimerization and DNA binding. Furthermore, AR and ESR1 recruit common co-
factors for both pathways.
Considering the above similarities between breast cancer and prostate cancer, as a future
work we plan to test our method on breast cancer to understand whether there are common
relevant protein coding genes and miRNAs in our top ranking list thus defining more possible
common pathways. Moreover, we plan to integrate other regulators of gene expression (e.g.
transcription factors) to find more complex regulatory networks and circuits.
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